Kurt E Hersberger
Overview
Explore the profile of Kurt E Hersberger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
121
Citations
1507
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bollinger A, Semedo Fortes M, Zu Schwabedissen H, Hersberger K, Stauble C, Allemann S
Pharmacy (Basel)
. 2025 Feb;
13(1).
PMID: 39998012
Pharmacogenetic (PGx) testing is a promising approach for optimizing drug therapies. However, there is limited knowledge regarding its real-world utilization and long-term impact in clinical practice. This study assessed how...
2.
Pharmacogenotyping disproves genetic cause of drug-related problems in family history: a case report
Bollinger A, Hersberger K, Zu Schwabedissen H, Allemann S, Stauble C
BMC Anesthesiol
. 2024 Nov;
24(1):416.
PMID: 39548363
Background: In clinical practice, family medication history is not routinely assessed as part of a patient's family health history (FHH). The information is self-reported and can depend on the individual's...
3.
Dietrich F, Zeller A, Hersberger K, Arnet I
BMJ Open Qual
. 2024 Jan;
13(1).
PMID: 38216295
Background: Non-adherence to antihypertensive agents is common, mainly because of the low perceived burden of high blood pressure. General practitioners (GPs) are unable to predict whether patients are adhering to...
4.
Dietrich F, Polymeris A, Albert V, Engelter S, Hersberger K, Schaedelin S, et al.
J Neurol
. 2023 Oct;
271(2):841-851.
PMID: 37831125
Background: Direct oral anticoagulants (DOAC) effectively prevent recurrent ischaemic events in atrial fibrillation (AF) patients with recent stroke. However, excellent adherence to DOAC is mandatory to guarantee sufficient anticoagulation as...
5.
Bollinger A, Jeiziner C, Zu Schwabedissen H, Hersberger K, Allemann S, Stauble C
Pharmacogenomics
. 2023 Sep;
24(14):739-746.
PMID: 37712172
A woman with ocular hypertension suffered from severe bradycardia, hypotension and syncope attacks in temporal relation with ophthalmic timolol application. Topically applied timolol is nasally absorbed and has been shown...
6.
Bollinger A, Stauble C, Jeiziner C, Wiss F, Hersberger K, Lampert M, et al.
Pharmgenomics Pers Med
. 2023 Jul;
16:693-706.
PMID: 37426898
Purpose: Pharmacogenetics (PGx) is an emerging aspect of personalized medicine with the potential to increase efficacy and safety of pharmacotherapy. However, PGx testing is still not routinely integrated into clinical...
7.
Jeiziner C, Zu Schwabedissen H, Hersberger K, Allemann S
Int J Clin Pharm
. 2023 Jun;
45(6):1378-1386.
PMID: 37338707
Background: Pharmacogenetic (PGx) testing and counselling (short: PGx service) in the community pharmacy is not routinely practiced. We propose a comprehensive pharmacist-led service where PGx information is integrated into medication...
8.
Arnet I, Dursteler K, Jaiteh C, Grossmann F, Hersberger K
Eur Addict Res
. 2023 Jun;
29(4):253-263.
PMID: 37302389
Introduction: Opioid agonist treatment (OAT) is the first-line treatment for opioid use disorder (OUD). Simultaneously, opioids are essential medicines in acute pain management. The literature is scarce on acute pain...
9.
Stampfli D, Imfeld-Isenegger T, Hersberger K, Messerli M
BMC Infect Dis
. 2023 Jun;
23(1):384.
PMID: 37286975
Background: Hepatitis C virus (HCV) infections are a public health burden worldwide and often go undetected until sequelae develop. Offering HCV screening for the different vulnerable populations in community pharmacies...
10.
Studer H, Imfeld-Isenegger T, Beeler P, Ceppi M, Rosen C, Bodmer M, et al.
Int J Clin Pharm
. 2022 Nov;
45(1):117-125.
PMID: 36327045
Background: During transitions of care, including hospital discharge, patients are at risk of drug-related problems (DRPs). Aim: To investigate the impact of pharmacist-led services, specifically medication reconciliation at admission and/or...